Related references
Note: Only part of the references are listed.Long-term adherence and response to botulinum toxin in different indications
John-Ih Lee et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)
Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins
Harald Hefter et al.
FRONTIERS IN NEUROLOGY (2021)
Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study
Harald Hefter et al.
JOURNAL OF NEUROLOGY (2020)
Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy
Uwe Walter et al.
NEUROLOGY (2020)
Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature
Sara Samadzadeh et al.
TOXINS (2020)
Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA
Harald Hefter et al.
TOXINS (2020)
SIAXI Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea
Wolfgang H. Jost et al.
NEUROLOGY (2019)
Immunogenicity Associated with Botulinum Toxin Treatment
Steven Bellows et al.
TOXINS (2019)
Long-term suppression of atrial fibrillation by botulinum toxin injection into epicardial fat pads in patients undergoing cardiac surgery: Three-year follow-up of a randomized study
Alexander Romanov et al.
HEART RHYTHM (2019)
High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy
Philipp Albrecht et al.
NEUROLOGY (2019)
Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia
Harald Hefter et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study
Marek Moll et al.
PARKINSONISM & RELATED DISORDERS (2018)
Clinical Practice: evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin
Maria Fiorella Contarino et al.
FRONTIERS IN NEUROLOGY (2017)
Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis
Margherita Fabbri et al.
NEUROTOXICITY RESEARCH (2016)
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache Report of the Guideline Development Subcommittee of the American Academy of Neurology
David M. Simpson et al.
NEUROLOGY (2016)
High Botulinum Toxin-Neutralizing Antibody Prevalence Under Long-Term Cervical Dystonia Treatment
Harald Hefter et al.
MOVEMENT DISORDERS CLINICAL PRACTICE (2016)
Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products
Juergen Frevert
DRUGS IN R&D (2015)
Postoperative MRI localisation of electrodes and clinical efficacy of pallidal deep brain stimulation in cervical dystonia
Thomas Schoenecker et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Full Parkinsonian Triad Induced by Pallidal High-Frequency Stimulation in Cervical Dystonia
Rene Reese et al.
MOVEMENT DISORDERS CLINICAL PRACTICE (2015)
Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis
Harald Hefter et al.
JOURNAL OF NEURAL TRANSMISSION (2014)
Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial
Jens Volkmann et al.
LANCET NEUROLOGY (2014)
Molecular basis for disruption of E-cadherin adhesion by botulinum neurotoxin A complex
Kwangkook Lee et al.
SCIENCE (2014)
Comparative immunochemical characteristics of botulinum neurotoxin type A and its associated proteins
Anne-Marie Bryant et al.
TOXICON (2013)
Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®
Jürgen Frevert
Drugs in research & development (2013)
The Prevalence of Primary Dystonia: A Systematic Review and Meta-analysis
Thomas D. Steeves et al.
MOVEMENT DISORDERS (2012)
Botulinum Neurotoxin Is Shielded by NTNHA in an Interlocked Complex
Shenyan Gu et al.
SCIENCE (2012)
Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins - a single cohort 4-year follow-up study
Harald Hefter et al.
BMJ OPEN (2012)
CT-guided intramuscular botulinum toxin A injections into the deep anterior neck muscles in patients with pure antecaput or antecollis
H. Hefter et al.
BASAL GANGLIA (2012)
Impact of posterior deep neck muscle treatment on cervical dystonia: Necessity to differentiate between abnormal positions of head and neck
Harald Hefter et al.
BASAL GANGLIA (2012)
Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies
M. Zouhair Atassi et al.
IMMUNOBIOLOGY (2011)
Studies on the dissociation of botulinum neurotoxin type A complexes
Karl-Heinz Eisele et al.
TOXICON (2011)
A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis
Harald Hefter et al.
BMJ OPEN (2011)
Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?
Juergen Frevert et al.
BIOLOGICS-TARGETS & THERAPY (2010)
Neutralizing Antibodies and Secondary Therapy Failure After Treatment With Botulinum Toxin Type A: Much Ado About Nothing?
Oliver Lange et al.
CLINICAL NEUROPHARMACOLOGY (2009)
Stimulation-induced parkinsonism after posteroventral deep brain stimulation of the globus pallidus internus for craniocervical dystonia
S. Elizabeth Zauber et al.
JOURNAL OF NEUROSURGERY (2009)
C-type lectins on dendritic cells: key modulators for the induction of immune responses
Yvette van Kooyk
BIOCHEMICAL SOCIETY TRANSACTIONS (2008)
Botulinum neurotoxin type A in urology: Antibodies as a cause of therapy failure
Heinrich Schulte-Baukloh et al.
INTERNATIONAL JOURNAL OF UROLOGY (2008)
Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A
G. Kranz et al.
NEUROLOGY (2008)
Immunological aspects of Botox®, Dysport® and Myobloc™/NeuroBloc®
D Dressler et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia
R Benecke et al.
NEUROLOGY (2005)
Clinical presentation and management of antibody-induced failure of botulinum toxin therapy
D Dressler
MOVEMENT DISORDERS (2004)
Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure
D Dressler et al.
JOURNAL OF NEUROLOGY (2003)
Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions
KR Aoki et al.
EUROPEAN JOURNAL OF NEUROLOGY (2001)
Share Paper
